Fokke M, Hesse B, Mortensen S A
Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Denmark.
J Nucl Med. 1994 Feb;35(2):266-8.
Recent studies suggest that cardiac uptake of 111In-labeled antimyosin monoclonal antibody may be estimated semiquantitatively by calculating a heart-to-lung activity ratio, with pulmonary uptake serving as a reference region.
We obtained 96 111In-antimyosin scintigraphs to monitor rejection occurrence after heart transplantation in 26 patients.
On five scintigraphs, the count rate density in ROIs over the lungs was markedly higher (mean 53% higher) than that in the immediately preceding and following scintigraphs, whereas the activity in the heart was essentially unchanged. Four of these scintigraphs coincided with ongoing pulmonary infection and the fifth with an occurrence of a high anti-CMV titer.
The mechanism of apparent nonspecific antimyosin accumulation in the lungs is uncertain, although increased capillary permeability may be one possibility. Attention should be given to activity in the lungs if this activity is used as a reference in studies of 111In-antimyosin uptake in the heart.
近期研究表明,通过计算心-肺活性比,以肺摄取作为参考区域,可对111铟标记的抗肌凝蛋白单克隆抗体的心脏摄取进行半定量评估。
我们获取了96份111铟-抗肌凝蛋白闪烁扫描图,以监测26例心脏移植患者排斥反应的发生情况。
在5份闪烁扫描图上,肺部感兴趣区的计数率密度明显高于(平均高53%)紧邻的前后闪烁扫描图,而心脏的活性基本未变。其中4份闪烁扫描图与正在发生的肺部感染相符,第5份与高抗巨细胞病毒滴度的出现相符。
肺部明显的非特异性抗肌凝蛋白蓄积机制尚不确定,尽管毛细血管通透性增加可能是一种原因。如果在研究111铟-抗肌凝蛋白在心脏中的摄取时将肺部活性用作参考,应关注肺部活性。